IP Library Granted Patent US 12,234,238
Granted Patent B2
US 12,234,238 · App. 17/177,756 · Granted Feb 25, 2025

Antimicrobial compounds and methods of making and using the same

Inventors: Erin M. Duffy (Deep River, CT); Ashoke Bhattacharjee (Cheshire, CT); Zoltan F. Kanyo (North Haven, CT); Joseph A. Ippolito (Guilford, CT); Andrea Marra (New Haven, CT)
Assignee: BIOVERSYS AG
C07D487/04A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,238
App. No.
17/177,756
Granted
Feb 25, 2025
Kind
B2
Abstract

The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals. In some embodiments, the present disclosure provides a compound of Formula (I): or a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer.

Claims (41)

1. A compound of formula (AA):

or a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer, wherein:

J is selected from

X is selected from a 5- or 6-membered heterocyclyl ring and phenyl, wherein each of the 5- or 6-membered heterocyclyl ring and phenyl is optionally substituted with one or more R x ;

Z is selected from

each of R 1 , R 2 , and R 3 is independently selected from H and C 1-3 alkyl, provided that one or two of R 1 , R 2 , and R 3 is H, and when two of R 1 , R 2 , and R 3 are H and the other is C 1-3 alkyl, or when one of R 1 , R 2 , and R 3 is H and the other two are C 1-3 alkyl;

or R 1 is Hand R 2 and R 3 together with the nitrogen atoms to which they are attached and the carbon atom connecting the two nitrogen atoms form a 5- or 6-membered ring;

R 4 is C 1-3 alkyl;

R 5 is selected from H and C 1-6 alkyl;

R 6 is selected from H, C 1-6 alkyl, C 2-6 alkenyl, and C 3-6 cycloalkyl, wherein the C 1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, OR a , SR a , —C(O)OR a , —SC(NH)NH 2 , C 3-6 cycloalkyl, and 3-6 membered heterocyclyl;

R 7 is selected from H and C 1-6 alkyl;

or R 6 and R 7 together with the carbon and nitrogen atoms to which they are attached form a ring having one of the formulas:

wherein the ring is optionally substituted on a ring carbon atom with C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with one or more OH;

or R 5 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting the two carbon atoms form a ring having one of the formulas:

wherein the ring is optionally substituted on a ring carbon atom with OH;

Q is selected from C 1-2 alkylene or —C(O)—;

R 21 is selected from H, C 1-6 alkyl optionally substituted with 1-3 halo;

R 8 is selected from H and halogen;

each R X is independently selected from halogen, C 1-6 alkyl, C 1-4 haloalkyl, OR C , N(R c ) 2 , —C(O)OR c , —C(O)R c , C 3-6 cycloalkyl, and aryl, wherein the C 1-6 alkyl is optionally substituted with one or more R b ,

or two adjacent R x come together with the atoms to which they are attached to form a 5- or 6-membered ring;

each R a is independently selected from H and C 1-6 alkyl;

each R b is independently selected from C 2-6 alkenyl, OR c , N(R c ) 2 , —C(O)OR c , C 3-6 cycloalkyl, OC(NH)NH 2 , and aryl;

each R c is independently selected from H, C 1-6 alkyl, aryl, —C(O) aryl, and —(CH 2 )aryl, wherein the C 1-6 alkyl and the aryl are each optionally substituted with one or more R d ; and

each R d is independently selected from C 1-3 alkyl, OH, O(C 1-3 alkyl), NO 2 , NH 2 , NH(C 1-3 alkyl), and N(C 1-3 alkyl) 2 .

2. The compound of claim 1 , wherein two of R 1 , R 2 , and R 3 are H, and the other is C 1-3 alkyl.

3. The compound of claim 1 , wherein two of R 1 , R 2 , and R 3 are H, and the other is methyl.

4. The compound of claim 1 , wherein one of R 1 , R 2 , and R 3 is H, and the other two are C 1-3 alkyl.

5. The compound of claim 1 , wherein one of R 1 , R 2 , and R 3 is H, and the other two are methyl.

6. The compound of claim 1 , wherein R 1 is H; and R 2 and R 3 together with the nitrogen atoms to which they are attached and the carbon atom connecting the two nitrogen atoms form a 5- or 6-membered ring.

7. The compound of claim 1 , wherein R 1 is H; and R 2 and R 3 together with the nitrogen atoms to which they are attached and the carbon atom connecting the two nitrogen atoms form an imidazoline.

8. The compound of claim 1 , wherein one of R 5 and R 7 is H and the other is C 1-6 alkyl.

9. The compound of claim 1 , wherein R 5 is H and R 7 is C 1-6 alkyl.

10. The compound of claim 1 , wherein R 5 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting the two carbon atoms form

11. The compound of claim 1 , wherein R 5 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting the two carbon atoms form

wherein the ring is optionally further substituted with C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with one or more OH.

12. The compound of claim 1 , wherein R 5 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting the two carbon atoms form

13. The compound of claim 1 , wherein R 5 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting the two carbon atoms form

14. The compound of claim 1 , wherein R 6 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting the two carbon atoms form

15. The compound of claim 1 , wherein R 6 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting the two carbon atoms form

16. The compound of claim 1 , wherein R 6 is selected from H and C 1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen and OR a .

17. The compound of claim 1 , wherein R 6 is H.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2023
From: MELINTA THERAPEUTICS, INC.; MELINTA SUBSIDIARY CORP.
To: BIOVERSYS AG
Reel/Frame 064043/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2023
From: DUFFY, ERIN M.; BHATTACHARJEE, ASHOKE; KANYO, ZOLTAN; IPPOLITO, JOSEPH; MARRA, ANDRA
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 064075/0664 →
CHANGE OF NAME Recorded Jun 23, 2023
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 064089/0895 →
Continuity (10)
Continuation 16622969
Provisional Application 62681498 · Jun 6, 2018
Provisional Application 62660747 · Apr 20, 2018
Provisional Application 62660782 · Apr 20, 2018
Provisional Application 62633454 · Feb 21, 2018
Provisional Application 62633554 · Feb 21, 2018
Provisional Application 62593445 · Dec 1, 2017
Provisional Application 62522574 · Jun 20, 2017
Provisional Application 62521835 · Jun 19, 2017
Related Publication 20210171533A1 · Jun 10, 2021
References Cited (7)
US 9193731B2 · Duffy · 2015 [cited by examiner]
US 10815238B2 · Kanyo · 2020 [cited by examiner]
US 10934295B2 · Duffy · 2021 [cited by examiner]
US 10934925B2 · Kim · 2021 [cited by examiner]
US 20230250101A1 · Duffy · 2023 [cited by examiner]
WO WO2011047319A2 · 2011 [cited by examiner]
Silverman. The Organic Chemistry of Drug Design and Drug Action, 2004, pp. 25-34 (Year: 2004). [cited by examiner]